Donovan B. Yeates

CEO at KAER Biotherapeutics Corporation

Donovan B. Yeates, Ph.D., CEO, KAER Biotherapeutics Corporation, is an internationally recognized authority in aerosol drug delivery and respiratory function. Has developed technologies to deliver aerosols to the lungs, quantify the dose delivered and evaluate the physiological mechanisms whereby they are cleared from the lungs. He is an inventor of aerosol generation and delivery technology to deliver fine particle solid-phase aerosols from viscous solutions at high dose rates. Dr. Yeates is an emeritus professor with over 90 publications and 16 patents. He has a Ph.D. in Medical Biophysics from the University of Toronto.


Title: Delivery of Therapeutic Aerosols to Critically Ill Patients